Increased FOG-2 in Failing Myocardium Disrupts Thyroid
Hormone-Dependent SERCA2 Gene Transcription C ongestive heart failure (CHF) is a lethal condition and represents the final common end point of many forms of heart disease. A hallmark feature of failing hearts is a downregulation of sarcoplasmic reticulum calcium ATPase (SERCA)2 and ␣-myosin heavy chain (␣MHC), which are critical components of the myocyte excitation-contraction coupling machinery. 1, 2 Although the regulatory mechanisms that affect these changes are poorly understood, a similar pattern of gene expression seen in the hypothyroid heart suggests that impaired thyroid hormone (T3) responsiveness may contribute to this transcriptional switch. 3 Indeed, T3 is required for the physiological increase of SERCA2 and ␣MHC after birth. 4 Low SERCA2 and ␣MHC expression levels in the hypothyroid or failing heart are recovered following T3 replacement. 5, 6 In heart failure models, decreased circulating T3 levels, 7 accelerated myocardial T3 turnover, 8 and altered thyroid hormone receptor (TR) isoform expression 9 have been implicated mechanisms of cardiacrestricted T3 resistance.
T3 regulates transcription through interaction with the ligand-binding domain of high-affinity nuclear TR proteins that recognize T3 response elements (TREs) on target genes. 10 Three major TR isoforms, TR␣1, TR␣2, and TR␤1, are expressed in the heart. TR␣1 and TR␣2 are abundantly expressed in the ventricular compact zone, which contributes the greatest force output from the heart, whereas TR␤1 expression is limited to the peripheral ventricular conduction system. 11 TR␣1, but not TR␤1, is required for normal SERCA2 and ␣MHC expression in vivo, and mouse TR gene deletion models support a predominant role for TR␣1 in the regulation of cardiac contractile and electrophysiological functions. 12 Without T3, TR proteins bind TREs and decrease basal gene expression through the recruitment of corepressor complexes. On T3 binding to TR, these complexes are displaced and coactivator proteins are recruited that modulate chromatin structure and enhance gene expression. 13 Because an imbalance favoring TR corepressor binding impairs T3 responsiveness, 14 -16 we considered whether a cardiacenriched corepressor protein may mediate local cardiac T3 resistance in CHF.
FOG-2 (friend of GATA-2) is a multi-zinc finger nuclear corepressor protein necessary for normal development of the heart and, in particular, the left ventricular (LV) compact zone. 17, 18 FOG-2 was originally identified as a GATA4-interacting protein 19, 20 but also interacts with nuclear hormone receptors, chicken ovalbumin upstream protein transcription factor (COUP-TF)2 21 and retinoid-X receptor-␣ (RXR␣). 22 In models of load-induced heart failure, GATA4, COUP-TF2, and RXR␣ regulate components of the cardiac gene program that affect natriuretic peptide expression, 21, 22 cardiac metabolism, 23 and myocyte architecture. 24 Although FOG-2 represses the transcriptional activities of GATA4, 19 COUP-TF2, 21 and ligand-bound RXR␣ 22 in cultured cardiomyocytes, the role of FOG-2 in the adult heart remains undefined.
Here, we report that FOG-2 levels are increased in human end-stage heart failure and in a mouse model of dilated cardiomyopathy. Transgenic (Tg) mice with targeted overexpression of FOG-2 in the heart have reduced systolic and diastolic function. Diminished expression of SERCA2 is a primary finding associated with the cardiomyopathy created by FOG-2 overexpression. We demonstrate that FOG-2 binds TR␣1 and impairs T3-mediated transcription of the SERCA2 promoter. Taken together, we identify a novel mechanism of cardiac resistance to T3 signaling caused by increased FOG-2 expression that may contribute directly to heart failure progression.
Materials and Methods

Mice
␣MHC-CREB-S133A Tg mice 25 and Fog-2 ϩ/Ϫ (heterozygous null) mice 17 were described previously. ␣MHC-FOG-2 Tg mice were produced following injection of a transgene including the full-length mouse FOG-2 cDNA (base pairs 132 to 4770) downstream of the murine ␣MHC promoter 26 into newly fertilized ICR (Taconic) mouse embryos. Founders identified by Southern blot analysis with FOG-2 probe (nucleotides 132 to 1207) were bred with ICR mice. Histological analysis was performed on hearts fixed in 4% paraformaldehyde and processed into paraffin blocks. Cardiac functional analysis was performed by echocardiography and cardiac catheterization (expanded Materials and Methods section, available in the online data supplement at http://circres.ahajournals.org). Protein and total RNA extracts for gene expression analysis were prepared using standard methods (online data supplement, expanded Materials and Methods section). Studies were approved by the Institutional Review Board for Animal Care and Use Committee at Tufts Medical Center and Harvard University.
Gene Expression Analysis
Northern blotting of total RNA was performed with [ 32 P]-labeled FOG-2 cDNA template (nucleotides 132 to 1207) and 18S probes (online data supplement, expanded Materials and Methods section). Quantitative real-time RT-PCR (qRT-PCR) was performed using cDNA synthesized from total RNA and amplified in triplicate with custom primer sequences (online data supplement, expanded Materials and Methods section). Western immunoblotting was performed with SERCA2 (Affinity BioReagents), calsequestrin (Upstate), GAPDH (Research Diagnostics), and FOG-2 (Santa Cruz Biotechnology) antibodies or FOG-2 antiserum, 26 followed by a species appropriate HRP-conjugated secondary antibody. Membranes incubated with ECL Plus (Amersham) were imaged on a Typhoon 9410 System (Amersham), and band densities were quantified using ImageQuant software (Amersham).
Adenovirus Infection
Full-length mouse FOG-2 cDNA (nucleotides 132 to 4770) was subcloned to generate a recombinant adenovirus expressing both FOG-2 and enhanced green fluorescent protein (EGFP) (Ad-FOG-2) using the AdEasy Adenoviral Vector System (Stratagene). 27 A control vector expressing ␤-galactosidase and EGFP (Ad-LacZ) was provided by the Adenoviral Core Facility (Tufts Medical Center). Primary cultures of neonatal rat ventricular myocytes prepared as previously described 28 were grown to 70% to 80% confluence. Media was exchanged with DMEM containing 2% charcoal-stripped fetal bovine serum. Neonatal rat ventricular myocyte cultures were infected with Ad-LacZ or Ad-FOG-2 for 12 hours and grown in media supplemented with vehicle (100 nmol/L NaOH) or T3 (Sigma). Infection at an approximate multiplicity of infection (moi) of 8 resulted in a Ͼ95% cellular EGFP expression at 72 hours (Nikon Eclipse E800). Cells were harvested for RNA at 48 hours and for protein at 72 hours using standard methods (online data supplement, expanded Materials and Methods section).
Interaction Assays
All plasmid constructs are detailed in the online data supplement (expanded Materials and Methods section). HEK-293 cells were transfected with equal parts pcDNA3-FOG-2 19 with either pCR3-rTR␣1 or pCR3-myc-rTR␣1 using Polyfect (Qiagen). Cellular extract was diluted in an immunoprecipitation buffer and precipitated with FOG-2 antiserum, 26 myc epitope antibody (Tufts University Core Facility), or no antibody (online data supplement, expanded Materials and Methods section) and immunoblotted with FOG-2 antiserum. 26 Glutathione S-transferase (GST) pull-down assays were performed with fusion proteins containing either zinc fingers 5 and 6 (amino acids 497 to 831) or zinc fingers 7 and 8 (amino acids 752 to 1151) 21 and recombinant rat TR␣1 and TR␣2 proteins labeled with [ 35 S]-methionine (Amersham) using the TnT T7 Coupled Reticulocyte System (Promega) (online data supplement, expanded Materials and Methods section).
Transient Transfection Assays
The p0.6kb-SERCA2-tk-luciferase, containing the proximal rat SERCA2 promoter fused to the thymidine kinase (tk) promoter, has been described previously. 29 All other plasmid constructs are described in the online data supplement (expanded Materials and Methods section). Embryonic chick ventricular myocytes were prepared as previously described 30 and grown to 90% to 95% confluence. Medium was replaced with DMEM containing 2% charcoal-stripped horse serum. Triplicate wells were each transfected with 150 ng of luciferase reporter plasmid, 400 ng of each expression vector (pcDNA3.1-hTR␣1, pcDNA-mFOG-2 or pCR3 to normalize amounts of transfected plasmid) and 10 ng of CMV-␤-galactosidase control vector using Lipofectamine 2000 (Invitrogen). After 18 hour, the media was replaced with DMEM/2% charcoal-stripped horse serum supplemented with vehicle or T3. After 24 hours the cells were lysed and luciferase (Promega) and ␤-galactosidase (Applied Biosystems) activity were measured using a luminometer (Thermo Labsystems). Fold activation is expressed as a ratio of luciferase activity to ␤-galactosidase activity and normalized across experiments to either the empty vector or FOG-2 reference condition.
Statistical Analysis
Microarray expression differences were determined by significance analysis of microarrays. 31 Statistically significant differences between Tg and nontransgenic (NTg) groups were determined by an unpaired t test or log-rank survival analysis when appropriate. All other statistical analyses were performed by 2-way ANOVA, followed by a Bonferroni post test using GraphPad Prism version 4.0 software. Data are expressed as meansϮSEM. A minimum value of PϽ0.05 was accepted as statistically significant.
Results
FOG-2 Protein Is Increased in Failing Hearts
To explore FOG-2 expression in the setting of heart failure, we analyzed microarray data (Gene Expression Omnibus GDS1362) from 37 human cardiac tissue samples taken from nonfailing (NF) (nϭ6), nonischemic cardiomyopathy (nϭ21), and ischemic dilated cardiomyopathy (nϭ10). 32 Significance analysis of microarrays identified FOG-2 as a differentially expressed gene among cardiomyopathy samples with a local false discovery rate of 0.06%. FOG-2 expression was increased 1.8-fold in nonischemic cardiomyopathy and 1.6 fold in ischemic dilated cardiomyopathy samples, respectively compared with nonfailing control (Figure 1a ).
To observe whether increased FOG-2 expression is associated with heart failure independent of concomitant therapy, we studied CREB-S133A mice, a well-characterized model of human dilated cardiomyopathy. These mice develop progressive chamber dilatation and contractile dysfunction by 8 weeks of age and begin to die from heart failure by 10 weeks of age. 25 Whereas 6-week-old CREB-S133A mice did not have significant differences in FOG-2 expression compared with NTg littermate controls (1.51Ϯ0.39-fold difference, Pϭ0.19), a 2.53Ϯ0.45-fold increase in FOG-2 protein (PϽ0.05) was observed at 12 weeks of age (Figure 1b) . Furthermore, increased myocardial FOG-2 protein expression was also observed in mice subjected to 14 days of transverse aortic constriction, at which time point, LV fractional shortening was significantly depressed ( Figure I in the online data supplement). Thus, increased FOG-2 expression is associated with decompensated heart function.
FOG-2 Tg Mice Develop Heart Failure
To determine the consequence of increased FOG-2 expression in the adult heart, we generated 5 lines of cardiacspecific Tg mice with FOG-2 expression driven by the ␣MHC promoter. 33 One line did not express FOG-2. The remaining 4 lines were found to have low (line 2467, FOG-2-low), medium (line 1711, FOG-2-med), and high (lines 2926 and 4102, FOG-2-high) levels of FOG-2 expression. Northern and Western blot analysis confirmed FOG-2 transgene expression in the heart (Figure 2a and 2b) .
Genotypic analysis performed at 3 weeks of age revealed equivalent numbers of Tg and NTg pups in all lines, suggesting that FOG-2 overexpression from the ␣MHC promoter did not influence viability during embryonic development. The FOG-2-med and -high lines demonstrated significant morbidity and mortality beginning as early as 6 weeks of age ( Figure  2c ) and were observed to have lethargy, tachypnea, and peripheral edema, consistent with overt heart failure. Hearts from FOG-2 mice displayed grossly normal-sized ventricles (Figure 2d ) and enlarged atria with mural thrombi (supplemental Figure IIA) . Cardiac valve leaflet structure was unremarkable (supplemental Figure IIB) . A trend toward greater whole heart mass relative to body weight in Tg versus NTg hearts (4.21Ϯ0.08 versus 3.97Ϯ0.09 mg/g, Pϭ0.06) was attributable to enlarged atria. The ventricular to body weight (3.5Ϯ0.1 versus 3.6Ϯ0.1 mg/g, PϭNS) and tibia length (5.9Ϯ0.2 versus 6.0Ϯ0.2 gm/mm, PϭNS) ratios were similar, as were cardiomyocyte cross-sectional areas (data not shown). Pico Sirius staining showed increased interstitial fibrosis (supplemental Figure III) , consistent with findings in cardiomyopathy 25 and hypothyroidism. 34 To evaluate the functional cardiac phenotype underlying the susceptibility to heart failure in FOG-2 mice, we assessed contractile performance in 8-to 10-week-old FOG-2-med Tg and NTg mice. FOG-2 mice had mildly dilated LV systolic dimensions by echocardiography with significantly reduced fractional shortening (Table) . Invasive pressure measurement showed reduced LV systolic pressure in FOG-2 mice (61.8Ϯ6.1 versus 82.4Ϯ6.7 mm Hg, PϽ0.05), whereas LV diastolic pressures were similar. At baseline, FOG-2 mice revealed a trend toward depressed systolic function (dP/dt max 2750Ϯ288 versus 3866Ϯ615 mm Hg/sec, Pϭ0.09) and diastolic relaxation (dP/dt min , Ϫ2242Ϯ258 versus Ϫ3471Ϯ578 mm Hg/sec, Pϭ0.05) that became significant following isoproterenol challenge (Figure 2d ).
SERCA2 Is a Downstream Target of FOG-2
Because FOG-2 mice demonstrated findings consistent with cardiomyopathy, gene expression was evaluated in 4-to 6-week-old FOG-2-high mice. FOG-2 mouse ventricles had increased B-type natriuretic peptide, ␤-myosin heavy chain (␤MHC), and atrial natriuretic factor (supplemental Figure  III) , almost significantly decreased ␣MHC expression (Pϭ0.06), and significantly decreased SERCA2 mRNA levels ( Figure 3a ) and protein levels (Figure 3b ), which were similarly observed in FOG-2-med mice (mRNA, PϽ0.01).
To address potential concerns of overexpression artifact, we also measured SERCA2 protein levels in Fog-2 ϩ/Ϫ (heterozygous null) mice. In this setting of reduced FOG-2 gene dosage, SERCA2 protein levels were increased nearly 2-fold (Figure 3c) .
To examine the effects of FOG-2 on endogenous SERCA2 expression independently from the potential secondary effects of heart failure, we infected cultured neonatal rat ventricular cardiomyocytes with a recombinant adenovirus expressing FOG-2. Ad-FOG-2 infection resulted in a dosedependent increase in FOG-2 protein and a significant dosedependent decrease in SERCA2 protein with maximal suppression of SERCA2 to levels that were half of that quantified in uninfected cells (Figure 4a and 4b) . T3 treatment increased SERCA2 expression; however, FOG-2 overexpression repressed this effect at the protein (Figure 4a and 4b) and transcript (Figure 4d ) levels. Importantly, FOG-2 did not alter expression of calsequestrin, another calcium-handling protein specific to cardiomyocytes (Figure 4c ). These results are consistent with SERCA2 being a downstream target of FOG-2 and show that FOG-2 abrogates T3-mediated transcription of the endogenous SERCA2 gene.
FOG-2 Physically Interacts With TR␣1
Because FOG-2 can bind nuclear hormone receptors, 21, 22 we explored the interaction of FOG-2 with TR␣1, the predominant regulator of SERCA2 expression in vivo. 11 In HEK-293 cells, FOG-2 was overexpressed with either TR␣1 or myctagged TR␣1. A FOG-2 antiserum recovered similar amounts of FOG-2 from both extracts (Figure 5a, right) . By comparison, the myc antibody recovered FOG-2 only when coexpressed with the myc-tagged TR␣1 (Figure 6a, middle) , thus identifying a specific association between FOG-2 and myc-TR␣1. Furthermore, in vitro-translated TR␣1 was retained by GST-FOG-2-Zn7-8, but not by FOG-2-Zn5-6 or GST alone, in the presence or absence of T3 (Figure 5b ). We also compared the retention of TR␣1 with TR␣2, an alternative product of the Thra gene that has a distinct C terminus (CT). 35 GST-FOG-2-Zn7-8 selectively retained the TR␣1-CT in the presence or absence of T3, but not the TR␣2-CT (Figure 5b) .
A functional analysis of the interaction of FOG-2 with TR␣1 was performed in transient transfection studies of cultured cardiomyocytes using a reporter plasmid regulated by 2 tandem repeats of the consensus TRE sequence ( Figure  5c ). Transfection of TR␣1 alone significantly repressed basal activity of the consensus TREϫ2-tk reporter by Ͼ50%, whereas T3 treatment increased activity by Ϸ8-fold. Although FOG-2 did not further repress activity beyond the level produced by TR␣1 in the absence of T3, FOG-2 significantly abrogated transactivation by TR␣1 following T3 treatment. Immunoblot analysis of cotransfected COS-7 cell lysates showed preserved, if not greater, TR␣1 protein expression when coexpressed with FOG-2, suggesting that the diminished reporter activity was not caused by lower TR␣1 protein levels (data not shown). Furthermore, whereas the FOG-2-R3A mutant, 36 which lacks repressive activity, permitted continued repression of basal reporter activity by TR␣1 in the absence of T3, the FOG-2-R3A mutant did not abrogateT3-mediated TR␣1 transactivation (Figure 5c ). Taken together, these results show a ligand-independent interaction between the CT of FOG-2 including zinc-fingers 7 to 8 (amino acids 752 to 1151) and the CT of TR␣1 and suggest that FOG-2 abrogation of T3-dependent TR␣1 transactivation requires the FOG-2 N-terminal repressive domain.
ECHOCARDIOGRAPHIC DATA IN FOG-2 TG AND NTG MICE
FOG-2 Abrogates T3-Mediated SERCA2 Promoter Activity
Further transient transfection studies of cultured cardiomyocytes were performed using a T3-responsive fragment of the SERCA2 promoter that includes multiple TREs. 37 To isolate the effect of FOG-2 on T3-mediated activation, we analyzed relative luciferase activity of the SERCA2-tk reporter 29 with respect to the basal effects of FOG-2 in the absence of T3. Similar to its effects on the consensus TREϫ2-tk reporter, FOG-2 did not further repress activity beyond the level produced by TR␣1 in the absence of T3 and significantly abrogated T3-mediated transactivation to basal levels ( Figure  6a ). Similar abrogation of T3-mediated activity was observed using heterologous tk promoters consisting of 3 tandem repeats of 2 SERCA2 TREs (TRE1 and TRE2) that preferentially bind TR␣1 (Figure 6b ). 37 Furthermore, although increasing doses of T3 activated the SERCA2-tk reporter in a dose-dependent manner, doses of T3 as high as 500 nmol/L could not overcome the negative effects of FOG-2 ( Figure  6c ). These results confirm that FOG-2 disrupts T3-mediated TR␣1 transactivation of the SERCA2 promoter.
Discussion
Our work demonstrates a novel role for FOG-2 in both adult heart disease and tissue-restricted T3 resistance. Increased FOG-2 expression in end-stage human heart failure, and at a time when CREB-S133A mice are susceptible to dying from heart failure, 25 and wild-type mice subjected to transverse aortic constriction have decreased systolic function, attests to the fact that FOG-2 upregulation is a novel heart-failure associated feature. We demonstrate that FOG-2 disrupts T3-mediated transcription of the SERCA2 gene, which in cultured cardiomyocytes, cannot be overcome by high doses of T3. By lowering SERCA2 expression, increased FOG-2 expression may therefore contribute to the impaired systolic and diastolic function characteristic of end-stage heart failure. These observations have clinical implications because thyroid hormone therapy, long considered for treating heart disease, has been limited by its cardiotoxic and peripheral side effects. 38 Downregulation of SERCA2 is a critical event that accompanies the transition to decompensated heart failure. 39 -41 We observed a novel physical interaction between FOG-2 and TR␣1, the principal TR-regulating SERCA2 in the myocardium. Furthermore, this interaction occurred in the absence and presence of T3, thus distinguishing FOG-2 from other corepressors whose binding affinities to nuclear hormone receptors are reduced by ligand. 42 Because the FOG-2-R3A inactive mutant did not abrogate T3-mediated TR-dependent transactivation but permitted intact TR-dependent silencing of a TRE-driven reporter, these results implicate that FOG-2 abrogation occurs via its highly conserved N-terminus repression motif, which has been shown to exert its effects via interactions with a nucleosome-associated complex. 36, 43 Alternatively, FOG-2 may impair T3-dependent transcriptional activity through competition with TR␣1 for limiting amounts of p300, 44 a coactivator required for T3-dependent transcriptional activity. 45 Repression of endogenous SERCA2 in the absence of T3 suggests that FOG-2 also represses SERCA2 through mechanisms unrelated to T3 signaling. Sequences further upstream of the proximal SERCA2 promoter studied in this report that positively regulate the SERCA2 promoter 46, 47 are enriched with GATA4 consensus binding sites 48 and have severely reduced transcriptional activity in severe LV pressure overload. 47, 48 Multiprotein complexes between FOG-2, GATA4, and other nuclear hormone receptors can cooperatively repress transcription 21, 22 and may also play a role in SERCA2 repression. Experiments are currently underway to address this question. without gross or histological evidence of hypertrophy, a commonly accepted precursor to load-induced heart failure. 49 The development of hypertrophy-independent cardiomyopathy in FOG-2 mice is reminiscent of several previously described mouse models of nonhypertrophic cardiomyopathy, including the Tg mutant CREB mouse 25 and human idiopathic restrictive cardiomyopathy. 50 Our findings suggest that FOG-2 may be a key downstream effector of signaling pathways responsible for mediating the transcriptional changes observed with heart failure via mechanisms independent of those which lead to pathological hypertrophy.
Recent studies supporting the necessary role of GATA4 for normal cardiac function and protection against load-induced heart failure 51,52 may also shed light on the role of FOG-2 in cardiomyopathy. FOG-2 is a powerful repressor of GATA4-mediated gene expression 19 and of cardiac myocyte hypertrophy in vitro. 44 Similar to FOG-2 mice, heterozygous mutant GATA4 mice have systolic and diastolic dysfunction and blunted dP/dt max and dP/dt min responses to ␤-adrenergic stimulation. However, in contrast to FOG-2 mice, they do not develop progressive dysfunction and death, despite a nearly 50% reduction of GATA4 protein. 51 FOG-2 mice also have more severe cardiac dysfunction and higher mortality than GATA4-deficient mice. 52 These results suggest that the effects of FOG-2 overexpression cannot be explained simply by a loss of GATA4 activity and implicate GATA4-independent functions of FOG-2. We speculate that although GATA4 is necessary for compensatory hypertrophy in response to pathological stress, 51 increased FOG-2 expression may directly trigger the transition to decompensated heart failure observed in end-stage cardiomyopathy.
Our study indicates that increased cardiac expression of FOG-2 promotes resistance of SERCA2 to T3 stimulation and may render the heart more susceptible to decompensation. This effect may extend broadly to other T3-regulated genes and pathways critical to efficient excitation-contraction coupling. Although it remains to be determined whether additional cardiac pathologies are associated with increased FOG-2 expression, our model suggests that therapies designed to decrease FOG-2 activity in the failing heart might slow the progression of heart failure. Defining the signaling pathways that regulate FOG-2 activity and the downstream targets of FOG-2 in cardiac myocytes will provide insight into mechanisms of heart failure progression. Fold Activation * p<0.001 * * Figure 6 . FOG-2 significantly abrogates T3-mediated SERCA2 promoter activity. Luciferase reporter assays performed in cultured cardiomyocytes cotransfected with empty vector or TR␣1 with empty vector or FOG-2 followed by treatment for 24 hours with vehicle or T3. Fold activation is expressed as relative luciferase activity normalized to either the vehicle-treated, empty vector control, or the vehicle-treated FOG-2 control when appropriate. Two-way ANOVA followed by Bonferroni was used for statistical analysis. a, Cotransfection of FOG-2 expression plasmid abrogated TR␣1 transactivation of the 0.6-kb SERCA2 luciferase reporter following T3 stimulation. *PϽ0.05 vs vector control (color-matched bar). b, Assays using reporter constructs driven by tk alone or with three tandem repeats of TRE1 or TRE2 from the rat SERCA2 proximal promoter. TR␣1 (shaded bars) silenced reporter activity in the absence of T3 and transactivated the reporter with T3 stimulation. FOG-2 abrogated T3-mediated TR␣1 transactivation. *PϽ0.05 vs vector control (black bar). c, Transactivation of 0.6-kb SERCA2 reporter by TR␣1 with indicated doses of T3 (nmol/L) was abrogated by FOG-2. *PϽ0.05 vs vector control (black bar). Data are from at least 3 independent experiments done in triplicate.
